Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 364

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type

Quartier, Pierre, Taupin, Pierre, Bourdeaut, Franck, Lemelle, Irène, Pillet, Pascal, Bost, Michel, Sibilia, Jean, Koné‐Paut, Isabelle, Gandon‐Laloum, Sylvie, LeBideau, Marc, Bader‐Meunier, Brigitte, Mouy, Richard, Debré, Marianne, Landais, Paul, Prieur, Anne‐Marie·2003·Arthritis & Rheumatism

Abstract

Objective: To assess the efficacy of etanercept in patients with juvenile idiopathic arthritis (JIA), and to assess the tolerance of these patients to etanercept. Methods: All JIA patients with active chronic polyarthritis, who were first treated with etanercept between November 1999 and June 2001 in 18 French centers because of poor response or intolerance to methotrexate, were included in this open‐label, prospective, multicenter study. A standardized questionnaire was sent to the treating physicians. We assessed the validated international core‐set score for JIA activity every 3 months and performed an intent‐to‐treat analysis. We also compared the risk of treatment failure in patients defined as having systemic‐onset, oligoarticular‐onset, or polyarticular‐onset JIA. Results: Sixty‐one patients were enrolled and were followed up for a median of 13 months. Treatment had to be stopped in 1 patient who became pregnant and in 12 patients due to severe side effects, including neurologic or psychiatric disorders, retrobulbar optic neuropathy, major weight gain, severe infection, cutaneous vasculitis with systemic symptoms, hemorrhagic diarrhea, uveitis flare, and pancytopenia. All of these side effects disappeared after discontinuation of etanercept. Crohn's disease was subsequently diagnosed in 1 child. Scores improved by ≥30% in 73% of patients after 3 months, but this proportion decreased to 39% after 12 months. The response rate was significantly lower in patients with systemic‐onset JIA than in those with oligoarticular‐ or polyarticular‐onset JIA. Conclusion: Treatment of JIA with etanercept may be associated with a wide spectrum of severe side effects. Although most patients initially respond to etanercept, this initial response is not always followed by sustained improvement over longer periods of time. In addition, the higher rate of treatment failure in the group with systemic‐onset JIA indicates that these patients in particular may require alternative treatments.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.10885

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 364

Metadata

Authors
Quartier, P., Taupin, P., Bourdeaut, F., Lemelle, I., Pillet, P., Bost, M., Sibilia, J., Koné‐Paut, I., Gandon‐Laloum, S., LeBideau, M., Bader‐Meunier, B., Mouy, R., Debré, M., Landais, P., & Prieur, A.
Venue
Arthritis & Rheumatism
Publisher
Wiley
Published
2003-04
Volume
48
Issue
4
Pages
1093-1101
ISSN
  • 0004-3591 (ISSN-L)
  • 1529-0131
OpenAlex
W2052604117
Cited by
364
References
20
FWCI
11.67
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.